ChiCTR2100050811 版本V1.6 版本创建时间2022/05/08 15:16:01 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100050811 

最近更新日期:

Date of Last Refreshed on:

2022-03-29 10:28:29 

注册时间:

Date of Registration:

2021-09-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

请与我们联系上传伦理审批文件。 800只近视眼睛的Kappa角分布

Public title:

Distribution of Angle Kappa in a Population of 800 Myopia Eyes

注册题目简写:

English Acronym:

研究课题的正式科学名称:

800只近视眼睛的Kappa角分布

Scientific title:

Distribution of Angle Kappa in a Population of 800 Myopia Eyes

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孙圣书 

研究负责人:

黄悦 

Applicant:

Sun Shengshu 

Study leader:

Huang Yue 

申请注册联系人电话:

Applicant telephone:

+86 15504151680

研究负责人电话:

Study leader's telephone:

+86 15620662542

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sshengshuamy@163.com

研究负责人电子邮件:

Study leader's E-mail:

1097813271@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市南开区复康路251号

研究负责人通讯地址:

天津市南开区复康路251号

Applicant address:

251 Fukang Road, Nankai District, Tianjin

Study leader's address:

251 Fukang Road, Nankai District, Tianjin

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津医科大学眼科医院

Applicant's institution:

Tianjin Medical University Eye Hospital

研究负责人所在单位:

天津医科大学眼科医院

Affiliation of the Leader:

Tianjin Medical University Eye Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020KY(L)-33

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

天津医科大学眼科医院伦理委员会

Name of the ethic committee:

Ethics Committee of Tianjin Medical University Eye Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

陈卓

Contact Name of the ethic committee:

Chen Zhuo

伦理委员会联系地址:

天津市南开区复康路251号

Contact Address of the ethic committee:

251 Fukang Road, Nankai District, Tianjin

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津医科大学眼科医院

Primary sponsor:

Tianjin Medical University Eye Hospital

研究实施负责(组长)单位地址:

天津市南开区复康路251号

Primary sponsor's address:

251 Fukang Road, Nankai District, Tianjin

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津医科大学眼科医院

具体地址:

南开区复康路251号

Institution
hospital:

Tianjin Medical University Eye Hospital

Address:

251 Fukang Road, Nankai District

经费或物资来源:

天津市临床重点专科(不同屈光手术方式后视觉质量和眼表情况的相关研究)项目

Source(s) of funding:

Tianjin Key Clinical Specialty Project (Study on Visual Quality and Ophthalmic Surface Conditions after Different Refractive Surgery Methods)

Target disease:

Refractive errors

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

研究400名近视患者(800只眼)的Kappa角与不同近视程度的关系、Kappa角的分布,及Keratron Scout和Pencacam两台仪器在测量Kappa角上的一致性,为角膜屈光手术的个性化设计提供更全面的参考。  

Objectives of Study:

To report the relationship between Angle Kappa and different refractive degree,there are 400 patients including this study. The aim of study is providing more comprehensive references for corneal refractive surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 在我院行角膜屈光手术的青年人(18周岁≤年龄≤40周岁);
2. 屈光度基本稳定≥2年(每年近视屈光度数增长不超过0.50 D);
3. 术前停戴软性角膜接触镜至少2周,停戴硬性角膜接触镜至少4周,矫正视力正常。

Inclusion criteria

1. Young people (aged 18 to 40 years) who underwent corneal refractive surgery in our hospital were selected;
2. The diopter is basically stable for >= 2 years (the annual increase of myopia diopter is no more than 0.50 D);
3. Stop wearing soft contact lens for at least 2 weeks and hard contact lens for at least 4 weeks before surgery, and the corrected visual acuity was normal.

排除标准:

1. 眼部存在活动性炎症;
2. 眼周化脓;
3. 眼附属器病变较为严重;
4. 伴青光眼;
5. 圆锥角膜;
6. 全身结缔组织疾病;
7. 精神疾病;
8. 糖尿病;
9. 全身感染性疾病或自身免疫性疾病。

Exclusion criteria:

1. Active inflammation of the eye;
2. Periocular suppuration;
3. Serious ocular accessory lesions;
4. Glaucoma;
5. Keratoconus;
6. Systemic connective tissue diseases;
7. Mental diseases;
8. Diabetes;
9. Systemic infectious diseases or autoimmune diseases.

研究实施时间:

Study execute time:

From 2021-09-01 00:00:00 To 2022-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-09-01 00:00:00 To 2022-09-01 00:00:00  

干预措施:

Interventions:

组别:

低中度近视组

样本量:

200

Group:

Mild-moderate myopia group

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

组别:

高度近视组

样本量:

200

Group:

High myopia group

Sample size:

干预措施:

干预措施代码:

Intervention:

no

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China 

Province:

Tianjin 

City:

 

单位(医院):

天津医科大学眼科医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Medical University Eye Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

Kappa角

指标类型:

主要指标

Outcome:

Angle Kappa

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

屈光度

指标类型:

主要指标

Outcome:

Refractive degree

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼压

指标类型:

次要指标

Outcome:

Intraocular pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼轴

指标类型:

次要指标

Outcome:

Axial length

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 40 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

no

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

以论文形式发表公开研究结果,对感兴趣的研究者可通过邮件联系

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publish public research results in a format paper, and interested researchers can contact by email.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2021-09-04 21:14:37